MedTrace Logo

Nutritional Supplements in Patients with Anorexia Nervosa

NCT05184738 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2025-02-14

No results posted yet for this study

Summary

Anorexia nervosa causes gastroparesis, constipation, and can lead to elevated liver enzymes. It is often necessary to supplement the diet of patients with nutritional formulas. The ingestion of a peptide formula, with partially hydrolyzed protein and rich in medium chain triglycerides, could favor its digestion and absorption, improving its tolerance and acceptance by the patient, compared to a polymeric formula.

Conditions

  • Anorexia Nervosa

Interventions

OTHER

Experimental Treatment, Oligomeric nutritional formula

Intervention group will receive a oligomeric nutritional formula (Bi1 peptidic Adventia Pharma, Spain).

OTHER

Control Treatment

Standard nutritional formula (isocaloric and isoprotein compared to the experimental treatment).

Sponsors & Collaborators

  • Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

    lead OTHER

Principal Investigators

  • Gabriel MD Olveira, PhD · Hospital Regional Universitario de Málaga, FIMABIS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
12 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-15
Primary Completion
2022-03-12
Completion
2022-05-22

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05184738 on ClinicalTrials.gov